Reverse stock split to maintain Nasdaq listing compliance; no fundamental change in value, but may affect perception and liquidity.
Impact on stocks 1
Biotech & Genomic Medicine
CDT
± MixedCapitalrelevance
CDT Equity Inc. has approved a 1-for-10 reverse stock split to maintain Nasdaq listing compliance. The split becomes effective July 17, 2026, at 5:00 pm Eastern Time, with shares expected to trade on a split-adjusted basis on Nasdaq under the ticker CDT starting July 20, 2026. Every 10 outstanding shares will be combined into one, reducing the share count to approximately 631,077, while the par value remains $0.0001 per share. No fractional shares will be issued; instead, stockholders will receive a proportional cash payment. The company's transfer agent, Continental Stock Transfer & Trust Co., will handle the exchange, and stockholders holding shares in brokerage accounts or book-entry form need take no action.
Reverse stock split to maintain Nasdaq listing compliance; no fundamental change in value, but may affect perception and liquidity.